In this reported case, the <sup>125</sup>I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. The gene discussed is KDR; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.